Compare Biogen Inc (BIIB) vs Quantum Computing Inc (QUBT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Quantum Computing Inc — how do they compare? Biogen Inc trades at $187.81 (market cap $28.34B), while Quantum Computing Inc trades at $8.39 (market cap $1.88B). The key difference: Biogen Inc is far larger — about 15.1× Quantum Computing Inc's market cap, and Biogen Inc is trading nearer its 52-week high, Quantum Computing Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | QUBT | |
|---|---|---|
Market Cap | $28.34B | $1.88B |
Sector | Health | Technology |
52-Week High | $216.63 | $24.62 |
52-Week Low | $122.68 | $6.31 |
Enterprise Value | $30.62B | $894.04M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Quantum Computing Inc. (QUBT) trades at $8.00, down 7.62% amid sector-wide selling pressure. The stock shows bearish technical signals with negative moving averages but oversold RSI readings. Fundamentally, the company reported a net loss of $18.67 million on minimal revenue of $682,000 in 2025, though it maintains strong analyst support with a $24.00 consensus price target representing 200% upside potential. Recent strategic acquisitions and commercial agreements highlight growth initiatives.
QUBT presents high-risk, high-reward potential with significant cash burn offset by promising technology positioning. The company's photonics-based quantum approach and government policy support provide growth catalysts, but profitability remains distant with negative margins. Investors face substantial execution risk amid competitive quantum computing landscape, though analyst consensus remains strongly bullish on long-term prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Quantum Computing Inc
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →
